Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
University of Toledo Medical Center CRS
mi
from
Toledo, OH
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
University of Toledo Medical Center CRS
mi
from
Toledo, OH
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Community AIDS Network/Comprehensive Care Clinic CRS
mi
from
Sarasota, FL
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Community AIDS Network/Comprehensive Care Clinic CRS
mi
from
Sarasota, FL
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Center of Translational AIDS Research, Lewis Katz School of Medicine at Temple University CRS
mi
from
Philadelphia, PA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Center of Translational AIDS Research, Lewis Katz School of Medicine at Temple University CRS
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Inova Heart and Vascular Institute CRS
mi
from
Falls Church, VA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Inova Heart and Vascular Institute CRS
mi
from
Falls Church, VA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Mount Sinai West Samuels CRS
mi
from
New York, NY
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Mount Sinai West Samuels CRS
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Infectious Disease Clinical and Translational Research Center (CTRC) CRS
mi
from
New York, NY
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Infectious Disease Clinical and Translational Research Center (CTRC) CRS
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
University of Arizona CRS
mi
from
Tucson, AZ
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
University of Arizona CRS
mi
from
Tucson, AZ
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Gaborone CRS
mi
from
Gaborone,
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Gaborone CRS
mi
from
Gaborone,
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
University of Miami Infectious Disease Research Unit at Jackson Memorial Hospital CRS
mi
from
Miami, FL
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
University of Miami Infectious Disease Research Unit at Jackson Memorial Hospital CRS
mi
from
Miami, FL
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Malcom Randall VA Medical Center CRS
mi
from
Gainesville, FL
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Malcom Randall VA Medical Center CRS
mi
from
Gainesville, FL
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Washington University Therapeutics (WT) CRS
mi
from
Saint Louis, MO
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Washington University Therapeutics (WT) CRS
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Palmetto Health Clinical Trial Department CRS
mi
from
Columbia, SC
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Palmetto Health Clinical Trial Department CRS
mi
from
Columbia, SC
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Augusta University Research Institute, Inc. CRS
mi
from
Augusta, GA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Augusta University Research Institute, Inc. CRS
mi
from
Augusta, GA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Whitman-Walker Health CRS
mi
from
Washington,
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Whitman-Walker Health CRS
mi
from
Washington,
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Georgetown University CRS (GU CRS)
mi
from
Washington,
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Georgetown University CRS (GU CRS)
mi
from
Washington,
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Capital Medical Associates, PC CRS
mi
from
Washington,
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Capital Medical Associates, PC CRS
mi
from
Washington,
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Infectious Diseases Clinic, Washington DC Veterans Affairs Medical Center CRS
mi
from
Washington,
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Infectious Diseases Clinic, Washington DC Veterans Affairs Medical Center CRS
mi
from
Washington,
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
James J Peters VA Medical Center CRS
mi
from
Bronx, NY
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
James J Peters VA Medical Center CRS
mi
from
Bronx, NY
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Los Angeles, CA
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Palm Springs, CA
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Sacramento, CA
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
San Diego, CA
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
San Francisco, CA
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Denver, CO
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Fort Pierce, FL
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Fort Pierce, FL
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Orlando, FL
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
West Palm Beach, FL
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Wilton Manors, FL
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Wilton Manors, FL
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Atlanta, GA
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Savannah, GA
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Savannah, GA
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Chicago, IL
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Indianapolis, IN
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Baltimore, MD
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Boston, MA
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Southfield, MI
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Southfield, MI
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Hillsborough, NJ
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Hillsborough, NJ
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Newark, NJ
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Newark, NJ
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Manhasset, NY
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Manhasset, NY
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
New York, NY
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Chapel Hill, NC
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Charlotte, NC
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Tulsa, OK
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Tulsa, OK
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Philadelphia, PA
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Bellaire, TX
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Bellaire, TX
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Dallas, TX
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Houston, TX
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Seattle, WA
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Ciudad Autonoma de Buenos Aires,
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Ciudad Autonoma de Buenos Aires,
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Cincinnati, OH
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Scottsdale, AZ
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Scottsdale, AZ
Click here to add this to my saved trials